When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
Pancreatic Cancer
PANCREATIC CANCER ADVISOR
FEATURED CONTENT
-
-
Gender Bias in Oncology: Q&A With Dr Narjust Duma
Women are less likely to be introduced by their professional title and most likely to be introduced by first name. -
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response. -
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that. -
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
PANCREATIC CANCER NEWS
Gene Fusions Found in Pancreatic, Biliary IOPNs
Development of Pancreatic Cancer Tx to Be Discontinued Following Disappointing Trial Results
A Model for Predicting the Risk of Healthy Organ Exposure in Patients With Locally Advanced Pancreatic Cancer Treated With SBRT
Resection Should Be Considered Even in Certain Smaller pNETs
Virtual Molecular Tumor Board May Aid Treatment Selection
Want to read more?
Please login or register first to view this content.
